Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01153906 · ClinicalTrials.gov registry record
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 1,516
- Enrollment target
NCT01153906 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,516 participants.
The verdict
NCT01153906 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 1,516 participants
- Enrollment target
Study Summary
The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (AIDs) following females who have received at the least the first dose of Cervarix® as part of their routine health care.
Interventions
- OTHER Data collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,516 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01153906
The ClinicalTrials.gov registry entry for NCT01153906 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,516 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Data collection is the first listed.
NCT01153906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01153906 about?
NCT01153906 is a clinical study titled "Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination". The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (AIDs) following females who have received at the least the first dose of Cervarix® as part of their routine health care.
What is the current status of trial NCT01153906?
This trial is currently completed. The enrollment target is 1,516 participants. The study started on 2010-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01153906?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT01153906?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.